Sartorius shines in the first quarter: sales and profits rise rapidly!

Sartorius shines in the first quarter: sales and profits rise rapidly!

Deutschland - The laboratory and pharmaceutical supplier Sartorius presented remarkable growth figures in the first quarter of 2025. Sales rose to 883 million euros, which corresponds to an increase of almost 8 % compared to the previous year. This is reported by the Weser-Kurier .

The adjusted result before interest, taxes and depreciation (EBITDA) increased by around 12 % to 263 million euros in the same period. At the same time, the EBITDA margin improved from 28.6 % in the previous year to 29.8 %. The adjusted net profit reached almost 85 million euros and thus recorded an increase of over 20 %.

forecasts and market development

for the rest of the year 2025 Sartorius assumes sales growth of around 6 %. The signs are good that the larger biocrocess division will contribute a decisive part to this growth. According to the company, 29 to 30 % of the group sales should remain as adjusted EBITDA. Possible effects of tariffs are not included in the margin forecast. The positive results were above the expectations of analysts and underpin the strong market position of Sartorius.

The biotechnology market, which Sartorius serves as a supplier, also shows continuing growth. The market had a volume of around $ 497 billion in 2020 and is expected to grow with an annual growth rate (CAGR) of over 9.4 % by 2027. This development is driven by innovations in molecular biology both in the therapeutic area and in the development of new medication, as the analysis of Global Market Insights

Influence of biotechnology

Especially the increase in chronic diseases leads to a growing need for medication discovery and development. Biotechnology plays a key role here and has an impact on various sectors, including medicine, pharmacy, food production and environmental protection. Important companies in the biotechnology market include Abbott, Amgen, Merck and Thermo Fisher Scientific, which are also continuously investing in new technologies and products.

The Covid 19 pandemic has led to disorders on the biotechnology market, but investments in the sector rose to over 13 billion USD in 2020. This shows that setbacks have also increased the pressure to invest in innovative solutions. Countries such as India, Brazil and China benefit from government initiatives that promote growth in the biotech sector.